In May, HRSA notified Merck that it was violating 340B requirements by surpassing the ceiling prices for outpatient drugs covered under the federal program.
“Given Merck’s continued refusal to comply, HRSA has referred this issue to the HHS Office of the Inspector General,” Emeka Egwim, PharmD, director of HRSA’s Office of Pharmacy Affairs, wrote in the letter.
Merck is the eighth such drugmaker that HRSA has referred for potential fines alongside AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Sanofi, United Therapeutics.
Penalties could total more than $6,000 per violation, according to an Oct. 21 news release from 340B Health.
Editor’s note: Becker’s reached out to Merck for comment and will update the article as more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
